USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

PortfoliosPositionsRebalanceAnalyzeOptimize Suggest Industries

US Market Closed: Feb 9, 20:16 PM 2012

NYSE 8081.25 1.73 Index Moved Down

NASDAQ 2927.23 11.37 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for ARDM...

Aradigm financials and fundamentals

Companies

Sectors

Advisers

More Actions
- Equity Search
- Advanced Search
- Filter Tops
- Adviser Directory
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatility
- Import Equities

0.13

Intraday

One Month

^(0.00)

3.70%

Embed Now

Diversification Suggestion

Use Aradigm to offset short term systematic risk or to hedge overall market volatility. The stock experiences unexpected downward movement. The market is reacting to new fundamentals

1 Month Beta vs NYSE ......... 0.22

As returns on NYSE increase, Aradigm returns are expected to increase less then the market. However, during bear market, the loss on holding Aradigm will be expected to be smaller as well

ARDM

OTCBB

Aradigm Corp

http://www.aradigm.com

510-265-9000

Trade Aradigm

Run Report

Correlation

Dr. Igor Gonda Ph.D.

Chief Officer, Pres and Director

Nancy E. Pecota

Chief Financial Officer, Principal

Norma L. Milligin

VP of HR

Aradigm fundamentals

Day Low	0.13	Open	0.13
P/B Ratio	11.25	Market Cap	25.7M
Volume	78038	Sector	Healthcare
Last Close	0.135	Founded	Yes
Last Traded	2/9/2012	Year High	Not Applicable
Percent Change	3.70%	EBITDA	-9.9M
Absolute Change	0.00	Time	Not Applicable
Book Value	0.012	EPS	-0.051
Employees	12	Day High	0.131
Target Price	0.83	Current EPS	-0.051
This Year EPS	-0.06	Next Year EPS	-0.06

Aradigm Performance

Aradigm Profile

Aradigm Corporation, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.